Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.35 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.35 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10592678 | 1.00 | CA2 (0.41) | CA2MAPK1GPR84FFAR1SMN1; SMN2 | |
| SCHEMBL21895808 | 0.87 | CA2 (0.45) | CA2MAPK1GPR84FFAR1SMN1; SMN2 | |
| SCHEMBL17909990 | 0.81 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL20961233 | 0.81 | ACE2 (0.47) | GPR84FFAR1SMN1; SMN2PLA2G2APLA2G5 | |
| SCHEMBL6207891 | 0.81 | ALDH1A1 (0.48) | CA2ACE2ALDH1A1CA1 | |
| SCHEMBL8028251 | 0.81 | ALDH1A1 (0.48) | CA2ACE2ALDH1A1CA1 | |
| SCHEMBL2232837 | 0.81 | ALDH1A1 (0.48) | CA2ACE2ALDH1A1CA1 | |
| SCHEMBL15537061 | 0.80 | TSHR (0.42) | SLC1A1ALDH1A1 | |
| SCHEMBL17909986 | 0.80 | GABRR1 (0.45) | ALDH1A1 | |
| SCHEMBL17909993 | 0.80 | ALDH1A1 (0.35) | SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0098457-B1 | (1S,2R,3R)- AND (1R,2S,3S)-NITRILO-1-CARBONYL-3-METHYL-2-OXY-HEPTANES AND -HEPT-5-ENES USEFUL IN THE TOTAL SYNTHESIS OF CYCLOSPORINS AND PROCESSES FOR THEIR PRODUCTION | SANDOZ AG (CH) | 1987-08-05 | — | — | EP | claimed |
| EP-0098457-A2 | (1S,2R,3R)- and (1R,2S,3S)-nitrilo-1-carbonyl-3-methyl-2-oxy-heptanes and -hept-5-enes useful in the total synthesis of cyclosporins and processes for their production | SANDOZ AG (CH) | 1984-01-18 | — | — | EP | claimed |
| EP-0034567-A2 | A method for the total synthesis of cyclosporins and novel cyclosporins | SANDOZ AG (CH) | 1981-08-26 | — | — | EP | claimed |
| US-6995139-B2 | Cyclic undecapeptide pro-drugs and uses thereof | DEBIOPHARM S.A. (CH) | 2006-02-07 | — | — | US | disclosed |
| EP-1379547-B1 | MODIFIED CYCLOSPORIN AS A PRO-DRUG AND USE THEREOF AS A MEDICAMENT | DEBIOPHARM SA (CH) | 2005-12-21 | — | — | EP | disclosed |
| US-20040138108-A1 | Pro-drug and use thereof as a medicament | OPHTHALMOPHARMA AG (CH) | 2004-07-15 | — | — | US | disclosed |
| CN-1507451-A | Cyclosporin-pro-drug and use thereof as a medicament | �±Ȱ·�ķ�ɷ�����˾ | 2004-06-23 | — | — | CN | disclosed |
| EP-1379547-A2 | PRO-DRUG AND USE THEREOF AS A MEDICAMENT | DEBIOPHARM S.A. (CH) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002085928-A2 | MODIFIED CYCLOSPORINE WHICH CAN BE USED AS A PRO-DRUG AND USE THEREOF | DEBIOPHARM S.A. (CH) | 2002-10-31 | — | — | WO | disclosed |
| EP-0471295-B1 | Protein precipitation reagent | ABBOTT LAB (US) | 1995-11-08 | — | — | EP | disclosed |
| EP-0296123-B1 | Cyclic peptolides | SANDOZ AG (CH) | 1994-08-31 | — | — | EP | disclosed |
| EP-0098456-B1 | PEPTIDES COMPRISING A (1S,2R,3R)- OR (1R,2S,3S)-1-NITRILO-1-CARBONYL-3-METHYL-2-OXY-HEPTANE OR -HEPT-5-ENE RESIDUE USEFUL IN THE TOTAL SYNTHESIS OF CYCLOSPORINS, AND PROCESSES FOR THEIR PRODUCTION | SANDOZ AG (CH) | 1989-05-24 | — | — | EP | disclosed |
| EP-0098457-B1 | (1S,2R,3R)- AND (1R,2S,3S)-NITRILO-1-CARBONYL-3-METHYL-2-OXY-HEPTANES AND -HEPT-5-ENES USEFUL IN THE TOTAL SYNTHESIS OF CYCLOSPORINS AND PROCESSES FOR THEIR PRODUCTION | SANDOZ AG (CH) | 1987-08-05 | — | — | EP | disclosed |
| US-4554351-A | STEREOISOMERS | SANDOZ LTD. (CH) | 1985-11-19 | — | — | US | disclosed |
| EP-0034567-B1 | A METHOD FOR THE TOTAL SYNTHESIS OF CYCLOSPORINS AND NOVEL CYCLOSPORINS | SANDOZ AG (CH) | 1984-11-07 | — | — | EP | disclosed |
| EP-0098457-A2 | (1S,2R,3R)- and (1R,2S,3S)-nitrilo-1-carbonyl-3-methyl-2-oxy-heptanes and -hept-5-enes useful in the total synthesis of cyclosporins and processes for their production | SANDOZ AG (CH) | 1984-01-18 | — | — | EP | disclosed |
| EP-0098456-A2 | Peptides comprising a (1S,2R,3R)- or (1R,2S,3S)-1-nitrilo-1-carbonyl-3-methyl-2-oxy-heptane or -hept-5-ene residue useful in the total synthesis of cyclosporins, and processes for their production | SANDOZ AG (CH) | 1984-01-18 | — | — | EP | disclosed |
| US-4396542-A | Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production | SANDOZ LTD. (CH) | 1983-08-02 | — | — | US | disclosed |
| EP-0034567-A2 | A method for the total synthesis of cyclosporins and novel cyclosporins | SANDOZ AG (CH) | 1981-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138108-A1 | Pro-drug and use thereof as a medicament | OGFR, OPRM1, OPRL1 | CA2 1820/4885MAPK1 1130/4885GPR84 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.